Sweden · Delayed Price · Currency is SEK Vitrolife AB Statistics
Total Valuation
Vitrolife AB has a market cap or net worth of SEK 11.54 billion. The enterprise value is 12.32 billion.
| Market Cap | 11.54B |
| Enterprise Value | 12.32B |
Important Dates
The last earnings date was Thursday, July 16, 2026.
| Earnings Date | Jul 16, 2026 |
| Ex-Dividend Date | May 6, 2026 |
Share Statistics
Vitrolife AB has 135.42 million shares outstanding. The number of shares has decreased by -0.08% in one year.
| Current Share Class | 135.42M |
| Shares Outstanding | 135.42M |
| Shares Change (YoY) | -0.08% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.03% |
| Owned by Institutions (%) | 65.95% |
| Float | 73.71M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 17.62 |
| PS Ratio | 3.40 |
| PB Ratio | 1.42 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 18.82 |
| P/OCF Ratio | 15.87 |
| PEG Ratio | 1.26 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.91, with an EV/FCF ratio of 20.09.
| EV / Earnings | n/a |
| EV / Sales | 3.63 |
| EV / EBITDA | 11.91 |
| EV / EBIT | 19.49 |
| EV / FCF | 20.09 |
Financial Position
The company has a current ratio of 3.64, with a Debt / Equity ratio of 0.20.
| Current Ratio | 3.64 |
| Quick Ratio | 2.76 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | 1.55 |
| Debt / FCF | 2.61 |
| Interest Coverage | 9.16 |
Financial Efficiency
Return on equity (ROE) is -46.53% and return on invested capital (ROIC) is 7.15%.
| Return on Equity (ROE) | -46.53% |
| Return on Assets (ROA) | 2.81% |
| Return on Invested Capital (ROIC) | 7.15% |
| Return on Capital Employed (ROCE) | 5.91% |
| Weighted Average Cost of Capital (WACC) | 12.46% |
| Revenue Per Employee | 3.07M |
| Profits Per Employee | -4.52M |
| Employee Count | 1,103 |
| Asset Turnover | 0.24 |
| Inventory Turnover | 3.18 |
Taxes
In the past 12 months, Vitrolife AB has paid 133.00 million in taxes.
| Income Tax | 133.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.16% in the last 52 weeks. The beta is 1.72, so Vitrolife AB's price volatility has been higher than the market average.
| Beta (5Y) | 1.72 |
| 52-Week Price Change | -41.16% |
| 50-Day Moving Average | 94.10 |
| 200-Day Moving Average | 112.76 |
| Relative Strength Index (RSI) | 39.02 |
| Average Volume (20 Days) | 207,966 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Vitrolife AB had revenue of SEK 3.39 billion and -4.98 billion in losses. Loss per share was -36.80.
| Revenue | 3.39B |
| Gross Profit | 2.01B |
| Operating Income | 632.00M |
| Pretax Income | -4.85B |
| Net Income | -4.98B |
| EBITDA | 988.00M |
| EBIT | 632.00M |
| Loss Per Share | -36.80 |
Balance Sheet
The company has 823.00 million in cash and 1.60 billion in debt, with a net cash position of -778.00 million or -5.74 per share.
| Cash & Cash Equivalents | 823.00M |
| Total Debt | 1.60B |
| Net Cash | -778.00M |
| Net Cash Per Share | -5.74 |
| Equity (Book Value) | 8.13B |
| Book Value Per Share | 60.04 |
| Working Capital | 1.60B |
Cash Flow
In the last 12 months, operating cash flow was 727.00 million and capital expenditures -114.00 million, giving a free cash flow of 613.00 million.
| Operating Cash Flow | 727.00M |
| Capital Expenditures | -114.00M |
| Depreciation & Amortization | 356.00M |
| Net Borrowing | -425.00M |
| Free Cash Flow | 613.00M |
| FCF Per Share | 4.53 |
Margins
Gross margin is 59.23%, with operating and profit margins of 18.64% and -146.99%.
| Gross Margin | 59.23% |
| Operating Margin | 18.64% |
| Pretax Margin | -143.04% |
| Profit Margin | -146.99% |
| EBITDA Margin | 29.14% |
| EBIT Margin | 18.64% |
| FCF Margin | 18.08% |
Dividends & Yields
This stock pays an annual dividend of 1.10, which amounts to a dividend yield of 1.29%.
| Dividend Per Share | 1.10 |
| Dividend Yield | 1.29% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 3 |
| Payout Ratio | n/a |
| Buyback Yield | 0.08% |
| Shareholder Yield | 1.37% |
| Earnings Yield | -43.19% |
| FCF Yield | 5.31% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Vitrolife AB is 129.60, which is 52.11% higher than the current price. The consensus rating is "Buy".
| Price Target | 129.60 |
| Price Target Difference | 52.11% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 4.84% |
| EPS Growth Forecast (3Y) | 27.11% |
Stock Splits
The last stock split was on May 17, 2018. It was a forward split with a ratio of 5.
| Last Split Date | May 17, 2018 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
Vitrolife AB has an Altman Z-Score of 2.94 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.94 |
| Piotroski F-Score | 7 |